Vineet Laboratories Ltd
Incorporated in 2003, Vineet Laboratories Ltd is in designing, developing, manufacturing of API Intermediates and Bulk Drugs
- Market Cap ₹ 31.9 Cr.
- Current Price ₹ 34.6
- High / Low ₹ 78.5 / 30.0
- Stock P/E
- Book Value ₹ 27.2
- Dividend Yield 0.00 %
- ROCE 6.65 %
- ROE 2.31 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 35.8%
- Company has a low return on equity of 8.90% over last 3 years.
- Working capital days have increased from 73.4 days to 126 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|
0.00 | 243.48 | 191.10 | 212.29 | 150.59 | 97.97 | |
0.01 | 235.33 | 177.94 | 204.63 | 143.39 | 99.78 | |
Operating Profit | -0.01 | 8.15 | 13.16 | 7.66 | 7.20 | -1.81 |
OPM % | 3.35% | 6.89% | 3.61% | 4.78% | -1.85% | |
0.00 | 0.39 | 0.29 | 0.12 | 0.46 | 1.01 | |
Interest | 0.00 | 2.67 | 2.09 | 3.38 | 4.78 | 4.80 |
Depreciation | 0.00 | 1.81 | 2.02 | 2.37 | 2.52 | 2.52 |
Profit before tax | -0.01 | 4.06 | 9.34 | 2.03 | 0.36 | -8.12 |
Tax % | 0.00% | 56.16% | 28.91% | 38.42% | -183.33% | |
-0.01 | 1.78 | 6.64 | 1.25 | 1.03 | -7.75 | |
EPS in Rs | -0.24 | 1.93 | 7.20 | 1.36 | 1.12 | -8.41 |
Dividend Payout % | 0.00% | 0.00% | 13.89% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -15% |
TTM: | -43% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -24% |
TTM: | -392% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -18% |
1 Year: | -38% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 9% |
Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|
Equity Capital | 0.41 | 9.22 | 9.22 | 9.22 | 9.22 | 9.22 |
Reserves | -0.01 | 17.40 | 24.00 | 24.46 | 25.51 | 21.55 |
0.00 | 12.48 | 26.51 | 31.09 | 44.30 | 40.57 | |
0.00 | 69.64 | 73.59 | 51.08 | 37.84 | 35.19 | |
Total Liabilities | 0.40 | 108.74 | 133.32 | 115.85 | 116.87 | 106.53 |
0.00 | 19.67 | 21.38 | 26.65 | 26.92 | 26.35 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.12 | 0.14 | 0.13 | 0.18 | 0.23 |
0.40 | 88.95 | 111.80 | 89.07 | 89.77 | 79.95 | |
Total Assets | 0.40 | 108.74 | 133.32 | 115.85 | 116.87 | 106.53 |
Cash Flows
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
0.00 | 27.49 | 7.63 | -9.62 | -11.43 | |
0.00 | -7.81 | -3.68 | -6.69 | 0.33 | |
0.00 | 18.62 | 11.96 | 0.27 | 10.69 | |
Net Cash Flow | 0.00 | 38.30 | 15.91 | -16.03 | -0.40 |
Ratios
Figures in Rs. Crores
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|
Debtor Days | 64.03 | 69.14 | 60.45 | 76.59 | |
Inventory Days | 73.12 | 109.19 | 97.79 | 158.26 | |
Days Payable | 114.08 | 161.20 | 73.90 | 103.37 | |
Cash Conversion Cycle | 23.07 | 17.13 | 84.34 | 131.48 | |
Working Capital Days | 27.91 | 27.89 | 65.75 | 126.43 | |
ROCE % | 34.08% | 23.13% | 8.69% | 6.65% |
Documents
Announcements
-
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
17 Apr - Company not classified as Large Corporate under SEBI circular.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Apr - Certificate issued by Venture Capital and Corporate Investments Private Limited in compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the …
- Closure of Trading Window 25 Mar
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
15 Feb - Newspaper Advertisement in Financial Express (English language) and Nava Telangana (Telugu language) regarding the Un-audited Standalone financial results for the third quarter and nine months …
-
Integrated Filing (Financial)
13 Feb - Approved unaudited financial results for Q3 FY2024.
Product Profile:
a) API Intermediates:[1] Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine
b) Fine Chemicals and Reagents:[2] IPTG, PNPP, X-Gal, ATCA, Butyl Lithium, Furaldehyde, Butylnitrite, Aminouracil, etc.